Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a large increase in short interest in March. As of March 13th, there was short interest totaling 500,465 shares, an increase of 24.7% from the February 26th total of 401,483 shares. Based on an average daily volume of 181,083 shares, the days-to-cover ratio is presently 2.8 days. Approximately 19.8% of the company’s stock are sold short.

Aspire Biopharma Stock Performance

Aspire Biopharma stock opened at $0.91 on Monday. The stock has a market capitalization of $2.46 million, a P/E ratio of -0.05 and a beta of 0.89. The company’s fifty day moving average price is $1.37 and its 200 day moving average price is $6.19. Aspire Biopharma has a 1 year low of $0.55 and a 1 year high of $35.01.

Institutional Investors Weigh In On Aspire Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASBP. Jane Street Group LLC grew its stake in shares of Aspire Biopharma by 2,252.1% during the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock worth $91,000 after purchasing an additional 658,886 shares in the last quarter. XTX Topco Ltd grew its stake in Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after buying an additional 237,620 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Aspire Biopharma in the 3rd quarter valued at $28,000. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, January 21st. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aspire Biopharma has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.